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Abstract
Background: Brain metastases (BM) from colorectal cancer (CRC) are a rare event. However, the implications for
affected patients are severe, and the incidence has been reported to be increasing. For clinicians, knowledge
about the characteristics associated with BM is important and could lead to earlier diagnosis and improved survival.
Method: In this paper, we describe the incidence as well as characteristics associated with BM based on a
systematic review of the current literature, following the PRISMA guidelines.
Results: We show that the incidence of BM in CRC patients ranges from 0.6 to 3.2 %. BM are a late stage phenomenon,
and young age, rectal primary and lung metastases are associated with increased risk of developing BM. Molecular
markers such as KRAS, BRAF, NRAS mutation as well as an increase in CEA and CA19.9 levels are suggested predictors
of brain involvement. However, only KRAS mutations are reasonably well investigated and associated with an increased
risk of BM.
Conclusion: The incidence of BM from CRC is 0.6 to 3.2 % and did not seem to increase over time. Development of
BM is associated with young age, lung metastases, rectal primary and KRAS mutation. Increased awareness of brain
involvement in patients with these characteristics is necessary.
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Background
Worldwide, colorectal cancer (CRC) is the third most
common cancer in men and second in women. CRC is
the fourth most common reason for cancer-related
death, and it is responsible for an estimated 8 % of
deaths resulting from cancer [1].
Brain metastases (BM) are a common complication of
lung cancer (40–50 % of cases), breast cancer (5–15 %),
testicular cancer (10–15 %), and melanoma (10 %). BM
from CRC are, however, relatively rare. BM are reported
to develop late in the disease, and the patients normally
have metastases to other organs before BM are diag-
nosed [2, 3]. The reported incidence of BM from CRC
may be increasing because of improved diagnostics and
increased survival of patients, but this is not well docu-
mented [2].
A diagnosis of BM is associated with increased mor-
bidity and mortality. The reported median survival after
a diagnosis of BM is 2.6 to 7.4 months, and only very
few patients survive more than 1 year [4–6]. Intensified
surveillance of patients at risk of BM development could
potentially lead to earlier detection, hereby increasing
the number of treatment options available and improving
prognosis [4]. To identify patients at risk of developing
BM, knowledge about patient characteristics associated
with BM is important.
Methods
We conducted a systematic review of the current litera-
ture, following PRISMA guidelines [5], to describe the
incidence of BM from CRC, and to identify characteris-
tics associated with increased risk of BM.
* Correspondence: troels.dreier.christensen.01@regionh.dk
1Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev
Ringvej 75, DK-2730 Herlev, Denmark
Full list of author information is available at the end of the article
© 2016 Christensen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Christensen et al. BMC Cancer  (2016) 16:260 
DOI 10.1186/s12885-016-2290-5
The complete search strategy in PubMed was ((brain
AND (metastases OR metastasis)) OR (brain neoplasms
AND (metastases OR metastasis)) OR cerebral metasta-
sis OR cerebral metastases OR cerebellar metastasis OR
cerebellar metastases OR CNS metastasis OR CNS
metastases) AND (colorectal cancer OR colorectal neo-
plasms OR cancer of the colon OR cancer of the rectum
OR adenocarcinoma colon OR adenocarcinoma rectum
OR adenocarcinoma colorectal OR colonic carcinoma
OR rectal carcinoma OR colonic neoplasm OR rectal
neoplasm). In EMBASE, the search was conducted by
combining subject headings brain metastases/with
colorectal adenoma/or colorectal cancer/or colorectal
carcinoma/or colorectal disease/or colorectal surgery/or
colorectal tumor/or metastatic colorectal cancer.
No automatic filters were applied to the searches. We
included pre-reviewed, human studies in English in pa-
tients with CRC in which the incidence of BM or char-
acteristics of patients developing BM were reported. We
excluded reviews, studies older than 1980, and studies
comprising less than 25 patients with CRC. We also ex-
cluded studies with a mixed tumor population in which
data from CRC patients were not presented separately. If
two studies described the same cohort of patients, only
the newest was included.
Full articles were obtained and analyzed when appro-
priate. Reference lists of retrieved relevant articles were
screened for additional material. Two authors (TDC and
DN) independently surveyed the literature. In case of
ambiguity or disagreement, a verdict was reached by
consensus.
In order to analyze incidence and patient characteris-
tics, eligible studies were selected for pooling of data
and calculation of weighted means. Studies were deemed
eligible if they included all patients diagnosed with CRC
and identified BM patients from this cohort. Studies
were only eligible if a diagnosis of BM was made while
the patients were alive. Studies were ineligible for pool-
ing of data if they identified their BM patients from
various populations consisting of selected patients with
CRC, e.g. patients with metastatic CRC (mCRC), or if it
was not clearly stated from what population patients
with BM were identified. Weighted mean of incidence
was calculated by dividing the sum of BM patients in
relevant studies with the sum of CRC patients in the
same studies. Weighted means of characteristics were
calculated as the sum of BM patients with the specific
characteristic in relevant studies divided by the sum of
BM patients in those studies.
To compare stage of disease at primary diagnosis,
Dukes and Astler-Coller classifications were translated
to the TNM staging system (stage A = stage 1, stage B =
stage 2, stage C = 3, and stage D = stage 4). If not stated
in the studies, 95 % confidence intervals (95 % CI) were
calculated for the incidence of BM, using the Clopper-
Pearson method for binomial data. A 95 % CI was not
possible to calculate for data with continuous outcome
because most studies did not report the sampling
variability.
Results
The searches were conducted on April 15, 2015 (Fig. 1,
consort diagram), and revealed 908 articles from
PubMed and 505 from EMBASE. Totally, 93 studies
were found eligible. Thirty-six were duplicates. Two
studies described the same cohort of patients, and the
oldest were excluded [6]. A further three relevant studies
were identified from reference lists and included, in-
creasing the total number to 59 studies (Table 1). All
studies were retrospective. Thirty-one studies had con-
secutively included patients. The rest either did not in-
clude consecutively or did not clearly state how patients
were included [4, 7–64].
Forty-one studies either identified BM patients from
patient populations that did not include all patients diag-
nosed with CRC, or did not report from what population
patients with BM were identified, and were not eligible
for pooling of data. Eighteen studies identified patients
with BM from populations including all patients diag-
nosed with CRC (Table 1). Two of the 18 studies were
autopsy studies and were therefore excluded from fur-
ther analysis, giving a total of 16 studies eligible for data
pooling [7, 8, 10–16, 18–24]. In all 16 studies, follow-up
on CRC patients continued until death or end of study
period, and none performed routine follow-up screening
for BM.
Incidence of BM in patients diagnosed with CRC
All 18 studies (Table 1 and Fig. 2) with patients diag-
nosed with CRC reported an incidence of BM between
0.6 and 2.9 % [7–24]. In the 16 studies eligible for
pooling of data, the total number of CRC patients was
100,825 and the number of BM patients was 1588,
resulting in an incidence of 1.55 % (95 % CI 1.48–
1.63 %).
The variation in the reported incidence between the
16 studies seemed to depend on sample size, with the
highest variation among studies with the fewest patients
(Fig. 3a). The reported incidence was also affected by re-
gion, with Asian studies reporting a lower incidence
(weighted mean = 1.21 %) than the American (weighted
mean = 1.82 %) and European (weighted mean = 1.55 %).
The variation in incidence did not seem to be explained
by different years of data collection (Fig. 3b).
Two autopsy studies reported the incidence of patients
diagnosed with CRC. The incidence was 2.7 % in an
American study which included all patients diagnosed
with CRC at a single hospital between 1959 and 1979
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[17]. In a more recent Dutch autopsy study, the inci-
dence was 0.93 %. However, brain autopsies were not
performed on all patients, which probably led to BM be-
ing underestimated [9].
Incidence of BM in other CRC populations
Several studies reported an incidence from various CRC
populations (Table 1), including three that also reported
an incidence in all patients with CRC [9, 13, 24].
Nine studies reported an incidence of BM in a cohort
of metastatic CRC (mCRC) patients. However, Hess et
al. collected data, at a single time point, 4 months after
referral of the patient to their hospital, and found an
incidence of 0.71 %, which probably reflected the
short follow-up [30]. Excluding this study, the inci-
dence in patients with mCRC was 2.5 to 23 % [9, 12,
23, 25–29].
Four studies reported on a cohort of patients that had
undergone liver metastasectomy, with incidences be-
tween 1.3 and 5 % [33–36], and a single study reported
an incidence of 13 % after removal of pulmonary metas-
tases [37].
Two studies included patients with rectal cancer only.
Hugen et al. reported an incidence of 1.1 % in a cohort
of 1530 patients with rectal cancer. However, the study
only included metastatic sites at first diagnosis of
metastatic disease, probably causing an underestimation
of incidence [9]. Chiang et al. included patients with
radically resected T3 or T4 rectal cancer. They reported
an incidence of BM after lung metastases of 22.6 %, of
3.6 % after liver metastases, and of 2.9 % after local me-
tastases [38].
Two studies included patients with colon cancer only.
The incidence was 2.5 % in an autopsy study of patients
who were diagnosed with colon cancer and had a nec-
ropsy performed at one of 16 hospitals [39]. The other
study included all colon cancer patients treated at one
hospital and found an incidence of 4 % [40].
Two studies reported an incidence of 1.1 to 1.3 % in
patients who had been surgically treated for stage 1–3
primary cancer [41, 42]. And the last study reported an
incidence of 1.8 % in patients who previously had surgi-
cally removed primary tumor or metastases [43].
Characteristics of patients with brain metastases
The majority of the 59 studies reported clinicopatho-
logical characteristics of BM patients (Table 2), but
only a few analyzed a statistical association. Of the 16
studies, eligible for pooling of data, only 14 described
the characteristics of all included BM patients [7, 8,
10–16, 18–21, 23].
Timing of brain metastases
The median age at BM diagnosis ranged from 56 to
73 years. Four studies reported a median age higher than
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Fig. 1 Consort diagram
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Table 1 Studies included
Studies Years Country No. CRC
patients




Inclusion criteria for patients
with CRC used in the studies.
Noura et al. [7] 1985–2006 Japan 2299 1.3 % (0.8–1.8 %) YES Clinical Diagnosed CRC
Suzuki et al. [8] 1979–2010 Japan 5345 2.6 % (2.2–3.1 %) - Clinical Diagnosed CRC
Hugen et al.b [9] 1991–2010 Netherlands 5817 0.9 % (0.7–1.2 %) NO Autopsy Diagnosed CRC
Tan et al. [10] 1995–2003 Singapore 4378 0.6 % (0.4–0.9 %) YES Clinical Diagnosed CRC
Mongan et al. [11] 1984–2006 USA 1620 2.3 % (1.7–3.3 %) YES Clinical Diagnosed CRC
Jung M et al. [12] 1995–2008 Korea 8732 1.5 % (1.2–1.7 %) YES Clinical Diagnosed CRC
Pramateftakis et al. [13] 1990–2009 Greece 670 0.7 % (0.2–1.7 %) YES Clinical Diagnosed CRC
Jiang et al. [14] 1991–2010 China 8220 0.7 % (0.6–0.9 %) - Clinical Diagnosed CRC
Tevlin et al. [15] 1988–2012 Ireland 4219 0.3 % (0.1–0.5 %) - Clinical Diagnosed CRC
Tanriverdi et al. [16] 2001–2012 Turkey 4864 2.7 % (2.3–3.2 %) - Clinical Diagnosed CRC
Temple et al. [17] 1959–1979 USA 999 2.9 % (2.0–4.1 %) YES Autopsy Diagnosed CRC
Naito et al. [18] 1967–1992 Japan 778 1.9 % (1.1–3.2 %) YES Clinical Diagnosed CRC
Hammoud et al. [19] 1980–1994 USA 8632 1.7 % (1.5–2.0 %) YES Clinical Diagnosed CRC
Ko et al. [20] 1970–1996 Taiwan 7153 0.7 % (0.6–1.0 %) - Clinical Diagnosed CRC
Zorrilla et al. [21] 1996–2000 Spain 378 2.4 % (1.1–4.5 %) YES Clinical Diagnosed CRC
Schouten et al. [22] 1986–1998 Netherlands 720 1.4 %. (0.7–2.5 %) - Clinical Diagnosed CRC
Barnholtz-Sloan et al. [23] 1973–2001 USA 42,817 1.8 % (1.7–2.0 %) YES Register Diagnosed CRC
Kim et al. [24] 1987–2009 Korea 4350 1.1 % (0.8–1.4 %) - Clinical Diagnosed CRCd
Sundermeyer et al. [25] 1993–2002 USA 1020 3.2 % (2.2–4.5 %) - Clinical mCRC
Yeager et al. [26] 2008–2012 USA 918 4.0 % (2.9–5.5 %) - Clinical mCRC
Chyun et al. [27] 1977–1989 USA 78 23.0 % (14.3–34.0 %) YES Clinical mCRC
Patanaphan et al. [28] 1979–1982 USA 163 3.0 % (0.7–6.2 %) YES Clinical mCRC
Tran et al. [29] 1996–2009 Australia and USA 524 5.15 % (3.4–7.4 %) - Clinical mCRC
Hess et al. [30] 1994–1997 USA 984 0.7 %c (0.3–1.5 %) - Clinical mCRC
Tie et al. [31] 1999–2009 Australia 46 - - Clinical mCRC
Khattak et al. [32] 2006–2011 Australia 2006 -e NO Clinical mCRCe.
Kemeny et al. [33] 2003–2013 USA 169 5.0 % (2.5–9.9 %) NO Clinical Liver metastasectomy +
chemotherapy
Yoshidome et al. [34] 1985–2001 Japan 207 4.0 % (1.7–7.5 %) YES Clinical Liver metastasectomy
de Jong et al. [35] 1982–2008 USA 1669 1.3 % (0.8–2.0 %) - Clinical Liver metastasectomy
Byrne et al. [36] 1987–2009 UK 1304 4.0 % (3.0–5.2 %) YES Clinical Liver metastasectomy
Higashiyama et al. [37] 1981–2001 Japan 100 13.0 % (7.1–21.2 %) YES Clinical Pulmonary metastasectomy
Hugen et al.b [9] 1996–1999 Netherlands 1530 1.1 % (0.6–1.8 %) - Clinical Rectal cancer
Chiang et al. [38] 2002–2006 Taiwan 884 -f YES Clinical Rectal cancer with T3 and T4
who had not received
neoadjuvant therapy
Weiss et al. [39] 1944–1984 Multiple 1541 2.5 % (1.8–3.4 %) - Autopsy Colon cancer
Cascino et al. [40] 1977–1980 USA 1006 4.0 % (2.9–5.4 %) YES Clinical Colon cancer
Takagawa et al. [41] 1992–2003 Japan 638 1.3 % (0.5–2.5 %) YES Clinical Verified radical resected
stages 1–3 tumor
van Gestel et al. [42] 2003–2008 Netherlands 5671 1.11 % (0.9–1.4 %) Yes Register Intended curatively treated
primary cancer stages 1–3.
Tokoro et al. [43] 1998–2010 Japan 1364 1.8 % (1.2–2.7 %) YES Clinical Surgically treated for primary
cancer and/or metastases
Scartozzi et al. [44] 1995–2005 Italy 99 - - Clinical Both primary and metastases
removed
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60 years. In seven studies eligible for pooling of data, the
age ranged between 55.7 and 73 years, and only two re-
ported a median age higher than 65 years. Only seven
studies reported that the age at primary CRC diagnosis
in patients with BM ranged from 54 to 70 years [10, 15,
18, 27, 51, 57, 58].
The interval from primary CRC diagnosis to BM diag-
nosis (BM-free interval = BMFI) was between 20 and
40 months in a total of 28 studies, and between
21 months and 34.3 months in 11 studies eligible for
pooling of data.
The BMFI after diagnosis of mCRC was 9–23 months
[12, 21, 51], 5–12 months after lung metastases [11, 38,
57], and 7.4–25 months after liver metastases [10, 36, 38].
There was no significant association between primary
tumor location and BMFI, but a tendency was noted to-
ward a shorter interval in patients with rectal tumor [53].
BMFI was statistically associated with the treatment re-
ceived between primary diagnosis and BM [19].
Barnholtz-Sloan et al. showed in their cohort of 42,817
CRC patients that the incidence proportion was statisti-
cally significantly higher in patients aged 50–59 (2.8 %),
compared to patients aged 40–49 (2.4 %) and 60–69
(2.2 %) [23]. Nieder et al. reported an increase in BMFI
in patients from the 1980s (6.5 months) to 2000s
(31 months) [52].
Gender
Thirty-seven studies reported the gender of BM pa-
tients. In these studies, 39 to 80 % were male. In 14
Table 1 Studies included (Continued)
Damiens et al. [4] 2000–2009 Canada 48 - YES Clinical BM
Kruser et al. [45] 1994–2005 USA 49 - - Clinical BM
Smedby et al. [46] 1987–2006 Sweden 1001 - YES Register BM
Fokas et al. [47] 1996–2007 Germany 78 - YES Clinical BM
Magni et al. [48] 2003–2013 Italy 41 - Yes Clinical BM
Farnell et al. [49] 1976–1993 USA 150 - YES Clinical BM
Kye et al. [50] 1997–2006 Korea 39 - - Clinical BM and survived more than
a month after BM diagnosis
Beak et al. [51] 2001–2009 Korea 118 - - Clinical BM treated with WBRT, SRS,
or surgery
Nieder et al. [52] 1983–2008 Norway 35 - YES Clinical BM treated with WBRT
Bartelt et al. [53] 1985–2000 Germany 47 - YES Clinical BM treated with WBRT
Heisterkamp et al. [54] 1989–2008 Germany 53 - - Clinical BM treated with WBRT
Matsunaga et al. [55] 1992–2008 Japan 152 - YES Clinical BM less than 3 cm and
treated with SRS
Schoeggl et al. [56] 1993–1996 Austria 35 - - Clinical BM treated with SRS
Wronski et al. [57] 1974–1993 USA 73 - YES Clinical BM treated neurosurgically
Fowler et al. [58] 1999–2007 Australia 32 - YES Clinical BM treated neurosurgically
Maglio et al. [59] 1999–2013 Italy 53 - Yes Clinical BM treated neurosurgically
Mege et al. [60] 1998–2009 France 28 - YES Clinical BM treated neurosurgically
Taher et al. [61] 1990–2009 Sweden 37 - - Clinical BM treated neurosurgically
D’Andrea et al. [62] 1960–2000 Italy 44 - - Clinical Single BM neurosurgically
treated
Simonova et al. [63] 1992–1998 Czech republic 30 - - Clinical Single BM radiosurgically
treated
Onodera et al. [64] 1979–1998 Japan 1077 - - Clinical Criteria unknown
Abbreviations: CRC Colorectal cancer, mCRC metastatic colorectal cancer, BM Brain metastases, WRBT Whole brain radiation therapy, SRS Stereotactic radiosurgery.
Dash(−) means not reported
aType of study: 1) Autopsy – studies where the patients were diagnosed based on autopsy 2) Clinic– studies where diagnosis are made radiological and authors
had access to patient history, surgery reports and so on. 3) Register – studies with information from register and where authors did not have access to patient
history or surgery reports
bThe study by Hugen et al. contained information from two different cohorts. One cohort of patients with primary CRC in which diagnosis was based on
autopsies, and a study based on radiological diagnosis that only included rectal cancer patients
cHess et al. did only follow-up on patients once for the study, 4 months after referral to the hospital, which could result in lower incidence
dKim et al. did not report characteristics of all 47 BM patients but only in 38 patients who received SRS treatment for BM
eKhattak et al. only report incidence of BM as only metastatic site of 0.4 %
fChiang et al. did not report incidence from the entire cohort but only selected groups, e.g. patients with lung metastases
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studies eligible for pooling of data, between 44 and
80 % of BM patients were male and the weighted
mean was 57.2 %.
The only study that examined the association between
gender and BM was Barnholtz-Sloan et al., who reported
a borderline significant higher incidence in male patients
(1.9 %) than in female patients (1.7 %), but their study
design did not make it possible to control for con-
founders [23].
Stage of primary disease
Twenty-six studies described the stage of primary tumor
at diagnosis of CRC. In these studies between 8 and
64 % had stage 4 disease, most of the studies reporting
more than 30 %. Generally stage 3 disease was the most
common among BM patients in the included studies. In
studies eligible for pooling of data, the weighted mean of
patients having stage 3 was 46.6 % and stage 4 was
36.2 % (Table 3).
Rectal location of primary tumor
Totally, 31 studies reported that the frequency of rectal
cancer among patient with BM ranged from 14 to 71 %.
Most studies reported a frequency of 40 to 60 %.
Thirteen studies were eligible for pooling of data, and in
these, 20 to 67 % of BM patients had rectal primaries, with
a weighted mean of 48.5 %. Both autopsy studies reported
that 41 % of BM patients had rectal primaries [9, 17].
A few studies tried to investigate whether rectal loca-
tion was associated with BM. Hugen et al. reported a
significantly higher incidence in rectal primaries (5 %)
compared to colonic (2.6 %) among mCRC patients [9].
Sundemeyer et al. found a higher but not significantly
increased incidence of BM in rectal cancer (4.4 vs 2.9 %)
patients [25]. One study found that rectal location in-
creased the hazard ratio, but not statistically significantly
[36]. Interestingly, an old study by Chyun et al. in mCRC
patients showed a higher incidence in CRC patients with
right-sided tumor than left-sided. However, this study
also reported a very high incidence of BM in the entire





















Fig. 2 Incidence of brain metastases in patients with colorectal cancer. Incidence of brain metastases (BM) from colorectal cancer (CRC) in the 19
studies that identified patient with BM from populations including all patients diagnosed with CRC. Error bars indicate 95 % confidence interval.
Gray: Studies with radiologically diagnosed brain metastases (17). Red: Autopsy studies (2). Blue: Pooled mean based on studies with radiologically
diagnosed brain metastases
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cohort (23 %), and their population might not reflect
BM patients in general [27].
Metastatic disease
Twenty-nine studies described the number of patients
with extracranial metastases at diagnosis of BM. It
ranged between 5 and 100 %. However, only one study
reported 5 % [24], and all other reported a frequency
higher than 63 %. Eleven of the studies eligible for pool-
ing of data detailed how many of their BM patients had
extracranial metastases, the incidence ranging from 73
to 100 %, with a weighted mean of 87.7 %.
A total of 32 studies described the prevalence of lung
metastases at BM diagnosis and found it to range from
36 to 92 %, more than half of the studies reporting that
70 % or more patients had lung metastases. The 11 stud-
ies eligible for data pooling found that 51 to 86 % of BM
patients had lung metastases at diagnosis, with a
weighted mean of 68.6 %. In the autopsy study by
Temple et al., 86.61 % of the patients had lung me-
tastases at autopsy [17]. Three studies reported an in-
cidence of BM in lung metastasis patients that ranged
from 6.2 to 22.6 % [25, 37, 38]. A few authors investi-
gated whether pulmonary metastases were associated
with an increased incidence of BM by comparing pa-
tients with lung metastases and patients without lung
metastases. Two studies showed that patients with
lung metastases had a significantly increased risk of
BM [25, 26]. Byrne et al. also reported an increased







































Fig. 3 Incidence according to no. patients, years and region of data collection. Incidence of brain metastases (BM) in the 17 studies that included
all patients diagnosed with colorectal cancer (CRC). Error bars indicate 95 % confidence interval. a - Incidence of BM according to size of cohorts.
Studies sorted by regions. b - Incidence of BM from CRC according to average year of data collection. Studies sorted by region
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Table 2 Characteristics of patients with brain metastases in all studies










Lung metastases Liver metastases
Characteristics of patients with brain metastases in studies including all patients diagnosed with colorectal cancer.
Noura et al. [7] 1985–2006 2299 29 61.1 (mean) 34.3 79 % 59 % 79 % 69 % 24 %
Suzuki et al. [8] 1979–2010 5345 142 61 22.8 61 % 43 % 78 % 66 % 42 %
Hugen et al. [9] 1991–2010 5817 54 - - - 41 % - - -
Tan et al. [10] 1995–2003 4378 27 66 27.5 52 % 56 % 93 % 82 % 51.9 %
Mongan et al. [11] 1984–2006 1620 39 - 25 54 % 43 % 100 % 78 %
Jung et al. [12] 1995–2008 8732 126 - 28.7 62 % 63 % 92.3 % 72 % 32.5 %
Pramateftakis et al. [13] 1990–2009 670 5 55.7 7.5 (mean) 80 % 20 % - - 80 %
Jiang et al. [14] 1991–2010 8220 60 62.5 21 60 % 50 % 88 % 65 % 30 %
Tevlin et al. [15] 1988–2012 4219 11 73 24 73 % 27 % 73 % - -
Tanriverdi et al. [16] 2001–2012 4864 133 - 31 53 % 56 % 89 % 65 % 51 %
Temple et al. [17] 1959–1979 999 29 - - 62 % 41 % - 86 % 76 %
Naito et al. [18] 1967–1992 778 15 - 22 53 % 67 % - 80 % -
Hammoud et al. [19] 1980–1994 8632 150 61 26 62 % 41 % 95 % 71 % 52 %
Ko et al. [20] 1970–1996 7153 53 - 33 74 % 62 % 77 % 54 % 26 %
Zorrilla et al. [21] 1996–2000 378 53 61 30 44 % 55 % 100 % 67 % 67 %
Schouten et al. [22] 1986–1998 720 9 - - - - - - -
Barnholtz-Sloan et al. [23] 1973–2001 42,817 779 - - 53 % - - - -
Characteristics of patients with brain metastases in studies including various selected cohorts of colorectal cancer patients.
Kim et al. [24] 1987–2009 4350 38a - - 66 % 58 % 5 % - -
Sundermeyer et al. [25] 1993–2002 1020 33 - - - - - - -
Yeager et al. [26] 2008–2012 918 37 - - - - - - -
Chyun et al. [27] 1977–1989 78 18 - 28 50 % - 95 % 55 % 22 %
Patanaphan et al. [28] 1979–1982 163 4 - 33 - - - - -
Tran et al. [29] 1996–2009 524 27 - - - - - - -
Hess et al. [30] 1994–1997 984 7 - - - - - - -
Tie et al. [31] 1999–2009 46 46 - - - - - - -
Khattak et al. [32] 2006–2011 2006 10 - - - - - - -
Kemeny et al. [33] 2003–2013 169 9 - - - - - - -
Yoshidome et al. [34] 1985–2001 207 8 - - - - - 75 % -
de Jong et al. [35] 1982–2008 1669 22 - - - - - - -












Table 2 Characteristics of patients with brain metastases in all studies (Continued)
Higashiyama et al. [37] 1981–2001 100 13 - - - - - - -
Hugen et al. second cohort [9] 1996–1999 1530 17 - - - - - - -
Chiang et al. [38] 2002–2006 884 - - - - - - -
Weiss et al. [39] 1944–1984 1541 38 - - - - - 68 % 74 %
Cascino et al. [40] 1977–1980 1006 40 60 25 60 % - 98 % 85 % 50 %
Takagawa et al. [41] 1992–2003 638 8 - - - - - - -
van Gestel et al. [42] 2003–2008 5671 63 - - - - 78 % - -
Tokoro et al. [43] 1998–2010 1364 25 - 25 52 % 48 % 92 % 92 % 68 %
Scartozzi et al. [44] 1995–2005 99 5 - - - - - - -
Kruser et al. [45] 1994–2005 49 49 66 23 67 % 14 % 82 % 47 % 33 %
Smedby et al. [46] 1987–2006 1001 1001 - 25 - - - - -
Fokas et al. [47] 1996–2007 78 78 - 20 39 % - 64 % - -
Magni et al. [48] 2003–2013 41 41 58 36 61 % 59 % 95 % 88 % 37 %
Farnell et al. [49] 1976–1993 150 150 65 23 58 % 30 % 81 % 57 % 29 %
Damiens et al. [4] 2000–2009 48 48 63 24 52 % 48 % 90 % 64 % 50 %
Kye et al. [50] 1997–2006 39 39 59 32 (mean) 59 % 56 % 97 % 80 % 41 %
Beak et al. [51] 2001–2009 118 118 58 - 53 % 61 % - 75 % 45 %
Nieder et al. [52] 1983–2008 35 35 - - - - - - -
Bartelt et al. [53] 1985–2000 47 47 - 23 - 51 % 100 % 50 % -
Heisterkamp et al. [54] 1989–2008 53 53 - - 47 % 36 % 77 % - -
Matsunaga et al. [55] 1992–2008 152 152 - 27 67 % 42 % 74 % 61 % 33 %
Schoeggl et al. [56] 1993–1996 35 35 - 28 66 % - 63 % 57 % 46 %
Wronski et al. [57] 1974–1993 73 73 61 28 41 % 40 % - 74 % 49 %
Fowler et al. [58] 1999–2007 32 32 66 28 66 % 31 % - 41 % 44 %
Maglio et al. [59] 1999–2013 53 53 65 - 42 % 43 % 96 % 75 % -
Mege et al. [60] 1998–2009 28 28 62 - 46 % 46 % - 36 % 29 %
Taher et al. [61] 1990–2009 37 37 63 35 54 % - - - -
D’Andrea et al. [62] 1960–2000 44 44 53 (mean) 26 75 % - - - -
Simonova et al. [63] 1992–1998 30 30 - - - - - - -
Onodera et al. [64] 1979–1998 1077 17 - - 77 % 71 % 88 % 76 % 47 %
Abbreviations: CRC Colorectal cancer, BM Brain metastases, BMFI brain metastases free interval (interval from primary diagnosis to BM development). Dash(−) means not reported












reported the prevalence of lung metastases to be
55 % in patients with BM compared to 27 % in pa-
tients without BM [27]. Hammoud et al. reported that
lung metastases did not affect overall BMFI [19].
Twenty-eight studies reported a prevalence of liver
metastases at BM diagnosis that ranged from 22 to
80 %, with half of the studies reporting less than 45 %.
Ten studies were eligible for pooling of data. Here, 24
to 80 % had liver metastases at BM diagnosis, with
a weighted mean of 40.6 %. The autopsy study by
Temple et al. reported a prevalence of 76 % in BM pa-
tients at autopsy [17]. Six studies reported an inci-
dence of 1.3 to 5 % after liver metastases. Four of
these only included patients who previously had liver
metastasectomy performed [33–36]. The two remaining
reported an incidence of 2.5 and 2.9 % after liver
metastases [25, 38]. Chiang et al. noted that the inci-
dence of BM after liver metastases was significantly
lower than after lung metastases [38]. Furthermore,
Sundemeyer et al. noted a statistically significant
decreased incidence of BM in patients with liver
metastases compared to patients without liver metastases
[25]. Chyun et al. reported a prevalence of liver metastases
of 22 % in patients with BM compared to 80 % in patients
without BM [27]. Liver metastases did not affect overall
BMFI [19].
Chemotherapy before BM development
Eleven studies included information about chemotherapy
before BM were diagnosed. The number of patients who
received chemotherapy before BM were diagnosed ranged
from 53 to 92 % in the studies [12, 16, 19, 21, 24, 25, 43,
47, 51, 52, 59]. Sundemeyer et al. showed that the inci-
dence of BM increased as the number of treatment lines
increased, but this was not statistically significant [25].
Tanriverdi et al. did not find any association between
amount of chemotherapy and incidence of BM [16].
Biomarkers
RAS were the most investigated DNA mutations asso-
ciated with BM. Mostly only KRAS was investigated,
but two studies also included NRAS mutation analysis
[26, 31]. Yeager et al. performed RAS mutation ana-
lysis in 918 CRC patients, and showed that patients
with NRAS and/or KRAS mutations had statistically
significant higher incidence of BM (6.1 vs. 1.9 % in
wild type patients), even after controlling for age,
tumor location and previous diagnosis of lung metas-
tasis [26]. A study by Kemeny et al. in CRC patients
who had hepatic metastases removed found the same
association between KRAS mutation and BM, but the
sample size was small and the association was not
statistically significant [33]. Both studies found KRAS
to be mutated more often in right-sided tumor than
in left-sided [26, 33]. Tie et al. showed a significantly
higher frequency of KRAS, but not NRAS mutation
in BM patients compared to non-BM patients [31].
Additionally, two studies showed a higher prevalence
of KRAS mutation than wild type in BM patients, but
the sample sizes were too small for adequate statistical
analysis [16, 48].
Ten studies analyzed carcinoembryonic antigen (CEA) in
association with BM, and the majority found an increased
level of CEA at BM diagnosis [7, 16, 18, 24, 36, 37, 40, 41,
50, 52]. Only Higashiyama et al. showed a potential predict-
ive role of CEA. They reported a higher incidence of
BM in patients with increased CEA level at pulmonary
metastasectomy compared to patients with a normal
level [37]. However, Byrne et al. did not find any associ-
ation between CEA level increase and BM development
[36]. Cancer antigen 19.9 (CA19.9) level was found to be
elevated before BM development in a study by Tanriverdi
et al., but no further analysis was made regarding this
discovery [16].
Mutation in PIK3CA has also been proposed as a pre-
dictor of BM development. Yeager et al. found an in-
creased incidence of BM in PIK3CA mutated patients
compared to wild type, but most of the mutated BM pa-
tients also had RAS mutation, which made the interpret-
ation difficult [26]. Tie et al. found an increased
prevalence of PIK3CA mutation in BM and lung metas-
tases compared to liver metastases, but could not show
any significant association between PIK3CA mutation
and BM development [31]. Two studies looked at BRAF
as a potential predictor of BM. Tran et al. showed an in-
creased incidence of BM in BRAF mutated compared to
BRAF wild-type, but the association was not statistically
significant [29], and Tie et al. did not find any associ-
ation between BRAF mutation and BM [31]. Neural cell
adhesion molecule (NCAM) has only been investigated
in one small study, which showed significantly increased
expression in primary tumors of BM patients compared
to non-BM patients [64]. Epidermal growth factor recep-
tor (EGFR) expression has also been investigated in
one study, but only five BM patients were included, of
whom two had EGFR expression in their BM [44].
Finally, C-X-C chemokine receptor type 4 (CXCR4)
expression was investigated in a study by Mongan et
al. CXCR4 expression in primary tumors was seen in
100 % of 11 BM patients, and only 50 % of ten patients
without BM [11]. Maglio et al. presented a study in
which they found O-6-methylguanine-DNA methyl-
transferase (MGMT) methylation to be elevated in
64.2 % of patients with BM, with high concordance
with primary tumors and independent of KRAS muta-
tion status. They compared this with results from
older studies showing lower level of methylation in
CRC patients without BM [59].
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Discussion
In this study we reviewed the current literature to de-
scribe the incidence of BM from CRC, and to identify
possible characteristics associated with BM develop-
ment. Table 3 summarizes our findings.
BM are a quite rare event in CRC patients. The inci-
dence of BM in CRC patients was reported to be any-
thing from 0.6 to 3.2 % in the studies included in this
review, and the weighted mean was 1.55 % (95 % CI
1.48–1.63 %). The difference reflects the small sample
sizes and statistical variation as well as regional differ-
ences, with Asian studies generally reporting a lower in-
cidence than studies from Europe and North America.
The true incidence of BM might be higher than what
has been reported in clinical studies because some pa-
tients had no symptoms, others did not receive brain
scans because of short life expectancy, and still others
were alive after the end of the study period. Autopsy
studies, however, report an incidence of 0.9 and 2.7 %,
which is comparable to what is found in clinical studies
[9, 17]. It has been suggested that the incidence of BM
from CRC is increasing due to better diagnostic options
and CRC patients living longer, but so far this has
remained speculative [2]. Smedby et al. showed that the
incidence of BM from all cancer types increased from
1987 to 2006 from 7/100,000 to 14/100,000 [46]. A study
by Schouten et al. did not, however, find any increase in
the incidence of BM [22]. In this review, we did not see
an association between years of data collection and inci-
dence of BM from CRC.
BM are a late stage phenomenon in CRC, and nat-
urally more common in patients who already have
metastatic disease, with an incidence ranging from
2.5to 23 % [9, 12, 23, 26–29]. In the studies included
in this review, BMFI was between 20 and 40 months,
and was shorter in patients with stage 4 disease
compared to stages 1–3 [19, 43, 48], and higher in
patients receiving more therapy between primary
diagnosis and BM than in those receiving less [19].
This was also consistent with the observation that
the BMFI increased from the 1980s to the 2000s,
probably resulting from better treatment and earlier
diagnosis of primary disease [52]. The shorter BMFI
observed in patients receiving less therapy could be
a result of a selection of patients who develop BM
shortly after primary diagnosis.
Only a few studies have reported patient age at pri-
mary CRC diagnosis; nevertheless, it is possible to con-
clude that patients with BM are usually younger than
the average patient with CRC. In the studies included in
our review, the median age at BM diagnosis was 62 years
or less in half of the studies, and only a few studies re-
ported it to be higher than 65 years. This can be com-
pared with the median age at primary diagnosis in CRC
patients being 67 years for men and 71 years for women
according to the US SEER register, and a similar result
was found by Hugen et al. in a European population [9,
65]. The young age could be a consequence of the long
BMFI, which makes it more likely for a young and
healthy individual to develop BM than an older patient
with several comorbidities, or it might reflect a more ag-
gressive disease in younger patients.
One observation drawn from this review is that more
men than women develop BM, but this difference has
Table 3 Summary of findings in our review on incidence and characteristics of patients with brain metastases from colorectal cancer
All studies Studies with CRC patients eligible for data pooling
No. studies Range No. studies No. CRC Patients No. BM patients Range Weighted mean (95 % CI)
Incidence of BM 36 0.4–23 % 16 100,825 1588 0.6–2.7 % 1.55 % (1.48–1.63 %)
Characteristics of BM patients
Median age (years) 20 55.7–73 7 52,591 716 55.7–73
Median BMFI (months) 28 20–40 11 56,618 794 21–34.3
Male 37 39–80 % 14 100,105 1578 44–80 % 57.2 % (54.7–59.8 %)
Stage of primary disease 25 12 48,556 673
- Stage 1 21 0–11 % 11 43,211 531 0–11 % 1.3 % (0.5–2.8 %)
- Stage 2 20 0–33 % 11 43,211 531 0–33 % 17.5 % (14.1–21.2 %)
- Stage 3 22 17–77 % 11 43,211 531 32–77 % 46.6 % (41.9–51.2 %)
- Stage 4 24 8–56 % 12 48,556 673 8–51 % 36.2 % (32.3–40.3 %)
Rectal primary 31 14–71 % 13 57,288 799 20–67 % 48.5 % (44.9–52.0 %)
Extracranial metastases 31 5–100 % 11 55,840 779 77–100 % 87.7 % (85.1–90.1 %)
Lung metastases 32 36–92 % 11 52,399 783 51–86 % 68.6 % (65.0–72.0 %)
Liver metastases 28 22–80 % 10 50,671 734 24–80 % 40.6 % (36.8–44.5 %)
Abbreviations: CRC Colorectal cancer, BM Brain metastases, BMFI brain metastases free interval (interval from primary diagnosis to BM development)
Christensen et al. BMC Cancer  (2016) 16:260 Page 11 of 14
not been investigated very thoroughly. The explanation
for this observation is likely that more male than female
patients develop CRC. Around 55 % of CRC patients are
male according to the GLOBOCAN 2012 [1]. This small
difference could possibly be the result of statistical
variation, but it cannot be ruled out that being male
increases the risk of BM, and new studies need to
investigate this.
In the studies included in this review, more than half of
the studies reported that 48 % or more of patients had rec-
tal primaries, and in studies eligible for data pooling, the
weighted mean was 48.5 %. This was a much higher num-
ber than what should be expected, since the incidence of
colon cancer was normally reported to be three times
higher than the incidence of rectal cancer [9, 65], and
therefore rectal cancer seems to be associated with an
increased risk of BM. However, this was only investigated
in a few studies and data were conflicting [9, 25, 27, 36].
Opposing this theory are two studies that looked at pa-
tients with colon cancer only and found an incidence of
2.5–4 %, which was higher than the incidence found in
CRC patients in general [39, 40].
Lung metastases have often been hypothesized to in-
crease the risk of BM development, and CRC patients
with lung metastases have an incidence of BM between
6.2 and 22.6 %, which is considerably higher than the
average incidence of BM even in mCRC patients [25, 37,
38]. A few authors also showed that patients with lung
metastases had a statistically significant increased risk of
BM [25, 26]. However, liver metastases did not seem to
increase the risk of BM, and the incidence after liver me-
tastases was reported to be 1.3–5 % [25, 33–36, 38]. Pa-
tients with liver metastases might even have a decreased
risk of BM compared to patients with lung metastases
[25, 38]. In our review, we found that about 70 % of BM
patients had lung metastases at diagnosis and about
40 % had liver metastases. This deviated from the nor-
mal pattern of metastases from CRC. In mCRC, liver
metastases are found in 70 % and pulmonary metastases
only in 30 % [9]. This suggests that there is a relation-
ship between lung metastases and BM, whereas it looks
like there may be a reverse relationship between BM and
liver metastases.
Several authors have presented theories to explain the
different metastatic patterns in patients with BM. The
most common hypothesis is that the pattern reflects the
vascular anatomy; the cancer can spread to the brain
through three principle routes: 1. through the portal vein
to the liver, and from there to the lung and thereafter
brain. 2. through the cava vein directly to the lung and
thereafter the brain. 3. through the vertebral plexus dir-
ectly to the brain [40, 48, 53]. The hypothesis explains
why fewer patients with liver than lung metastases de-
velop BM as well as the shorter BMFI after lung
metastases compared to liver metastases. It also explains
why rectal primaries increase the risk of BM, since the
rectum drains more often through the cava vein than the
colon.
A different hypothesis is that different molecular pat-
terns of the cancer explain the pattern of metastases
[11]. RAS mutations are the most thoroughly investi-
gated, and RAS mutations have been associated with
both increased incidence of BM and lung metastases
[16, 26, 31, 33, 48]. However, this does not seem to ex-
plain why more BM patients have rectal primaries than
average CRC patients, since RAS mutations are more
often found in right-sided colon tumors than in rectal
tumors [26, 33]. The association between BM and muta-
tion in PIK3CA and BRAF, expression of NCAM, EGFR,
and CXCR4, MGMT methylation and increase in the
tumor marker CA19.9 have also been investigated, but
only in one or two studies each and on small samples,
so the possible predictive potential is hard to determine
[11, 16, 26, 29, 31, 44, 59, 64]. The tumor marker CEA
has been found elevated at BM diagnosis in several studies
[7, 16, 18, 40, 41, 50], but only one study showed a pos-
sible predictive role of CEA, while one did not [36, 37].
CEA is usually used to monitor patients with CRC during
therapy [66], and CEA is elevated (above 5 ng/ml) in
approximately 70 % of patients with metastatic dis-
ease [67]. None of the studies have shown that an in-
crease in CEA observed in patients with BM differs
from that seen in patients with extracranial progres-
sion. Therefore CEA should not be considered as a
specific marker of BM development, but as a general
marker of tumor activity. However, one could argue
that in the absence of visible extracranial tumor pro-
gression and increased CEA, brain involvement
should be suspected. Besides these biomarkers investi-
gated in clinical studies and presented here, several
potential biomarkers have been found in animal and
in vitro models elsewhere [68].
Increased awareness of specific characteristics can po-
tentially increase the chance of early diagnosis of BM,
which may lead to lower total number of BM and better
performance status, ultimately increasing the potential
number of treatment options [4]. From our review, it is
clear that BM from CRC is a rare event, and it is not ne-
cessary to screen all patients. However, in patients with
rectal primary, lung metastases, and/or KRAS mutation,
increased awareness of BM is advisable.
This study had some limitations. First, we only had
access to published material from the included stud-
ies. Second, in many of the included studies it was
not possible to determine whether patients were con-
secutively included or not. This, in combination with
all studies being retrospective, leads to a risk of publi-
cation bias. Many of the papers presented incidence
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from a population spanning long periods of time, lim-
iting the conclusion on temporal variations. Most of
the present studies contained few BM patients, and
did not have sufficient strength or the right study de-
sign to clarify which factors increase the risk of BM.
We recommend that physicians enter new large scale
prospective clinical studies, preferably as international
collaborations, to determine risk factors for brain
involvement.
Conclusions
The incidence of BM from CRC ranges from 0.6 to
3.2 %, and it did not seem to increase over time. BM are
a late stage phenomenon and patients are usually youn-
ger than the average CRC patient. Rectal primary, lung
metastases and KRAS mutation are associated with an
increased risk of BM, and increased awareness of brain
involvement in patients with these characteristics is
necessary.
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